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We compared the performance of Organon Teknika’s NucliSens and Roche Diagnostic Systems’ Monitor
quantitative human immunodeficiency type 1 RNA assays. Both had similar linearity and sensitivity over most
of the dynamic range of the assays, although the Monitor assay was superior at the low range of RNA values
while the NucliSens assay was more consistent at higher RNA values. NucliSens generally showed less
interassay variability.
The advent of techniques that reliably quantify levels of
human immunodeficiency virus type 1 (HIV-1) RNA in patient
plasma has been pivotal in the development of new insights
into in vivo viral dynamics and HIV disease pathogenesis (2).
Various commercial RNA quantification techniques differing
in sensitivity, dynamic range, and variability have now been
introduced into clinical practice (4, 5). In this study we com-
pare performance characteristics of an improved nucleic acid
sequence-based analysis (NASBA) assay (NucliSens; Organon
Teknika, Durham, N.C.) with the reverse transcription-PCR
Amplicor Monitor assay (Roche Diagnostic Systems, Branch-
burg, N.J.).
(The results of this study were presented in part at the 12th
World AIDS Conference, Geneva, held from June 28 to July 3,
1998 [1a].)
Plasma samples were obtained from adult and pediatric pa-
tients recruited into clinical trials of antiretroviral therapies.
Informed consent was obtained from all patients or their legal
guardians prior to enrollment in the studies. Plasma was sep-
arated from anticoagulated blood within 6 h of collection in
EDTA or acid-citrate-dextrose and stored at 270°C until an-
alyzed. All samples were tested on either the first or second
thaw. Spiked plasma sample standards, provided by the Virol-
ogy Quality Assurance Laboratory (VQAL; Rush-Presbyterian
Hospital, Chicago, Ill.; sponsored by the Division of AIDS,
NIH), containing a known number of HIV RNA copies (9)
were used in direct comparisons of the assays and as external
standards in all experiments with patient samples.
Both the Monitor and the NucliSens assays were performed
following the manufacturers’ instructions. Because of the non-
normal distribution of RNA concentrations, continuous vari-
ables were analyzed following log transformation, usually by
nonparametric statistical methods. HIV RNA concentrations
that were undetectable or invalid in one or both of the assays
were omitted from statistical analysis. All analyses were per-
formed with Statview 4.5 software (Abacus Concepts, Berke-
ley, Calif.).
Twofold serially diluted plasma samples containing between
250 and 2,000 HIV RNA copies/ml were tested in four or five
replicates of both assays. Eight aliquots with nominal RNA
concentrations greater than 500 copies/ml gave detectable re-
sults with both assays. Of the 10 plasma samples containing
fewer than 500 copies/ml, 7 had detectable RNA results with
Monitor and 6 had detectable results with NucliSens.
Serial threefold dilutions were made of 4 HIV-1-seropositive
patient plasma specimens containing high concentrations of
HIV RNA (4.2 3 106 to 6.7 3 106 copies/ml) and tested in
both assays. A total of 36 samples were tested. Three samples
containing more than 106 HIV-1 RNA copies/ml gave invalid
results with Monitor, one sample with a predicted value of 640
copies/ml was undetectable in both assays, and two samples
with predicted concentrations of 1,920 and 320 RNA copies/ml
were undetectable by NucliSens but gave values of 1,011 and
212 copies/ml with Monitor. The mean overall difference be-
tween the results of serially diluted specimens was closer to the
true dilution factor and showed less variability when Monitor
was used (Table 1). The linearity of Monitor was better than
that of NucliSens in the lower half of the dynamic range
(,104.4 to 104.75 RNA copies/ml), while the linearities of both
assays were comparable in the upper range (Table 1). Log-
transformed RNA values from the four dilution series were
combined to perform linear regression analysis of the Nu-
cliSens- and Monitor-derived results against predicted RNA
levels. The curve generated with Monitor provided a very close
one-to-one linear fit (y 5 1.002x 2 0.058, r 5 0.997), whereas
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TABLE 1. Comparative linearities of Monitor and NucliSens
quantitative HIV-1 RNA assays
Value typea
Log10 difference (mean 6 SD) in HIV-1
RNA copies/ml with each threefold dilutionb
Monitor NucliSens
Overall 0.49 6 0.19 0.45 6 0.24
High 0.46 6 0.14 0.44 6 0.11
Low 0.51 6 0.24 0.46 6 0.36
a The arbitrary cutoff between “high” and “low” putative HIV-1 RNA values
was between 26,000 and 54,000 copies/ml in each dilution series.
b A true threefold dilution is approximately 0.48 log10.
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NucliSens had a linear relationship (y 5 0.921x 1 0.262, r 5
0.964).
Spiked plasma samples containing known quantities of
HIV-1 RNA (0, 1.5 3 104, 1.5 3 105, 7.5 3 105, or 1.5 3 106
copies/ml), provided by the VQAL, were analyzed in replicate
runs with Monitor (88 runs with each standard, with 7.5 3 105
copies/ml as the high standard) and NucliSens (69 runs, with
1.5 3 106 copies/ml as the high standard). Both assays showed
a high degree of reproducibility. The interassay variability,
given by the standard deviation of the log values of replicate
assays, was narrower for NucliSens than for Monitor. The
reproducibility of NucliSens improved progressively with
higher input copy number, while the interassay variability of
Monitor remained constant at around 0.20 log10 from 1.5 3
104 to 7.5 3 105 RNA copies/ml (Table 2). HIV-1 RNA con-
centrations obtained with Monitor were, on average, 0.27 log10
(close to twofold) greater than those generated by NucliSens
P , 0.0001) (Table 2). All samples containing zero copies of
HIV RNA were negative, giving a specificity of 100% for both
assays.
Quantitative HIV-1 RNA analysis was performed with both
the Monitor and the NucliSens assays on plasma samples from
51 HIV-seropositive patients being treated with a variety of
FIG. 1. HIV-1 RNA concentrations in patient samples tested by NucliSens plotted against data obtained with Monitor, before (a) and after (b) adjustment by using
VQAL standards. The solid line is the line of unity. (c and d) Difference between log10 Monitor and NucliSens data plotted against the mean of the log10 HIV-1 RNA
concentrations measured with the two assays, before (c) and after (d) adjustment.




Log10 HIV-1 RNA copies/ml
(mean 6 SD) P
Monitor (n 5 88) NucliSens (n 5 69)
15,000 (4.18) 4.29 6 0.20 4.02 6 0.18 ,0.0001a
150,000 (5.18) 5.27 6 0.18 5.00 6 0.14 ,0.0001a
750,000 (5.88) 5.88 6 0.23 NAc
1,500,000 (6.18) NA 5.96 6 0.10 ,0.0001b
a Two-tailed P value obtained by unpaired t-test comparison between log10
values obtained by Monitor and NucliSens.
b Unpaired t test comparing mean differences between log10 obtained with
NucliSens and Monitor and actual input RNA log10 copy number of 6.18 in the
case of NucliSens and 5.88 for Monitor.
c NA, not applicable.
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antiretroviral drugs or receiving no treatment. Log-trans-
formed HIV-1 RNA values that were above the level of de-
tection limit of both assays (n 5 41) were compared before and
after adjustment with a regression equation, making use of the
nominal log10 RNA concentration in external VQAL stan-
dards run concurrently with patient samples (1, 9). The con-
cordance between the assays for RNA detectability was 92%,
with three samples which were negative by Monitor measuring
630, 1,100, and 1,200 copies/ml (1,181, 643, and 382 copies/ml,
respectively, after adjustment) by NucliSens and one sample
which was negative by NucliSens measuring 1,192 copies/ml
(384 copies/ml after adjustment) with Monitor. In seven sam-
ples where unadjusted HIV RNA concentrates were detect-
able at less than 1,000 copies/ml with at least one assay, all but
one had detectable levels by both methods.
In the 41 samples testing positive by both methods, the
median unadjusted HIV RNA value with NucliSens was 2.51 3
104 compared with 3.98 3 104 copies/ml with Monitor (P 5
0.016 by Wilcoxon signed rank test). This difference persisted,
although to a lesser degree, after adjustment using the results
of concurrently run standards (median NucliSens HIV RNA
concentration of 3.09 3 104 compared with 3.32 3 104 cop-
ies/ml by Monitor; P 5 0.081). Simple regression analysis (Fig.
1a and b) showed a close linear relationship between the re-
sults obtained with the two assays, with little change following
adjustment in the correlation coefficient (r 5 0.880 and P ,
0.001 after, compared with r 5 0.872 and P , 0.001 before
adjustment), but much closer approximation to equivalence
(y 5 0.931x 1 0.167, compared with y 5 0.815x 1 0.685, where
y is log NucliSens and x is log Monitor HIV RNA concentra-
tion). The disparity between NucliSens and Monitor in these
patient samples was greater at lower RNA levels before and
after adjustment (Fig. 1c and d).
In this study we compared the performance characteristics
of NucliSens isothermal HIV-1 RNA amplification with those
of Roche Monitor reverse transcription-PCR, which is already
in widespread clinical use. The linearities of Monitor and Nu-
cliSens assay were comparable from approximately 500 to
1,000,000 RNA copies/ml, although Monitor had superior lin-
earity and sensitivity in the lower range and performed variably
at RNA levels greater than 1,000,000 copies/ml. These results
resemble those found in comparisons of Monitor with the
previous generation NASBA assay, which has a lower detec-
tion limit of 1,000 RNA copies/ml (3, 8). Both assays gave
correlation coefficients and linear slopes close to unity when
compared with the nominal RNA concentrations present in
serially diluted samples. Both assays were close to 100% sen-
sitive in detecting HIV-1 RNA in samples containing $1,000
copies/ml and had comparable sensitivities between 60 and
70% for RNA concentrations between 250 and 1,000 copies/
ml.
Interassay variability assessments made with replicate mea-
surements of standard HIV RNA concentrations were similar
for both assays. NucliSens had lower interassay variability,
especially at higher RNA concentrations (Table 2). Within
both assays, linearity and reproducibility fell away at levels
close to the lower detection limit. Direct comparison of the two
assays made with seropositive patient samples showed that
they correlated closely in their ability to detect viral RNA and
in actual quantitative RNA measurement. Following adjust-
ment by regression on the measured concentration of concur-
rently run VQAL standards, there was some improvement in
the agreement between the assays with respect to the absolute
HIV-1 RNA concentration, though this was not as marked a
correction as has been reported in previous comparisons of
Monitor and NASBA (1, 9). On the other hand, following
adjustment, the linear regression equation relating log10 Nu-
cliSens values to log10 Monitor values much more closely re-
sembled the line of equivalence, with an increase in the slope
from 0.82 to 0.93 and a reduction in the intercept from 0.69 to
0.17.
In conclusion, the two assays appear to have similar perfor-
mance characteristics. The linear dynamic range of NucliSens
extends above 106 RNA copies/ml and thus may be more
suitable for assessing viral load in infants and children, who
usually have higher HIV-1 RNA concentrations than adults (6,
7). In contrast, the linearity, and probably the sensitivity, of the
Monitor assay is superior in the lower range.
This study was funded in part by NIH contracts AACTG96VD006
and PACTG97PVCL06.
We thank Don Brambilla for helpful discussions.
REFERENCES
1. Brambilla, D., S. Leung, J. Lew, J. Todd, S. Herman, M. Cronin, D. E.
Shapiro, J. Bremer, C. Hanson, G. V. Hillyer, G. D. M. Sherry, R. S.
Sperling, R. W. Coombs, and P. S. Reichelderfer. 1998. Absolute copy
number and relative change in determinations of human immunodeficiency
virus type 1 RNA in plasma: effect of an external standard on kit compari-
sons. J. Clin. Microbiol. 36:311–314.
1a.Dyer, J. R., C. D. Pilcher, R. Shepard, J. Schock, J. J. Eron, and S. A. Fiscus.
1998. Abstr. 42162. 12th World AIDS Conference, Geneva, Switzerland.
2. Finzi, D., and R. F. Siliciano. 1998. Viral dynamics in HIV-1 infection. Cell
93:665–671.
3. Griffith, B. P., M. O. Rigsby, R. B. Garner, M. M. Gordon, and T. M.
Chacko. 1997. Comparison of the Amplicor HIV-1 Monitor test and the
nucleic acid sequence-based amplification assay for quantitation of human
immunodeficiency virus RNA in plasma, serum, and plasma subjected to
freeze-thaw cycles. J. Clin. Microbiol. 35:3288–3291.
4. Lew, J., P. Reichelderfer, M. Fowler, et al. 1998. Determinations of levels of
human immunodeficiency virus type 1 RNA in plasma: reassessment of
parameters affecting assay outcome. J. Clin. Microbiol. 36:1471–1479.
5. Lin, H. J., L. E. Myers, B. Yen-Lieberman, et al. 1994. Multicenter evalua-
tion of methods for the quantitation of plasma HIV-1 RNA. J. Infect Dis.
170:553–562.
6. Mofenson, L. M., J. Korelitz, W. A. Meyer, et al. 1997. The relationship
between serum human immunodeficiency virus type 1 (HIV-1) RNA level,
CD4 lymphocyte percent, and long-term mortality risk in HIV-1 infected
children. J. Infect. Dis. 175:1029–1038.
7. Shearer, W. T., T. C. Quinn, P. LaRussa, et al. 1997. Viral load and disease
progression in infants infected with human immunodeficiency virus type 1.
N. Engl. J. Med. 336:1337–1342.
8. VanDamme, A. M., J. C. Schmit, S. van Dooren, et al. 1996. Quantification
of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA
QT and the AMPLICOR HIV Monitor test. J. Acquired Immune Defic.
Syndr. 13:127–139.
9. Yen-Lieberman, B., D. Brambilla, B. Jackson, J. Bremer, R. Coombs, M.
Cronin, S. Herman, D. Katzenstein, S. Leung, H. J. Lin, P. Palumbo, S.
Rasheed, J. Todd, M. Vahey, and P. Reichelderfer. 1996. Evaluation of a
quality assurance program for quantitation of human immunodeficiency
virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology
laboratories. J. Clin. Microbiol. 34:2695–2701.
VOL. 37, 1999 NOTES 449
